Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate

SEATTLE and YONGIN, South KoreaNov. 5, 2018 /CNW/ — Curevo, a Seattle-based biotechnology company owned by GC Pharma, one of the largest therapeutic protein manufacturers in the world, announced today that the U.S. Food and Drug Administration (FDA) has advanced the company’s Investigational New Drug (IND) application for CRV-101. The vaccine candidate for the prevention of herpes zoster (shingles) is now cleared to proceed into a Phase 1 clinical trial in healthy adults.

Read the full article by GC Pharma

Share on facebook
Share on twitter
Share on linkedin
Back to Top